In this paper, we tested whether engineered exosomes could achieve targeted delivery of miR-25 and miR-181a to the brain of SCA3 mice and whether miR-25 and miR-181a could alleviate neuropathology by reducing the ATXN3 level in vivo. This evidence concerns the gene ATXN3 and Spinocerebellar ataxia type 3.